Novartis’s total energy use or consumption (on-site and purchased) in 2024 was 5,800 Tera Joules (TJ). The company’s energy usage reduced by 57.26% from 2016 levels and was down by 7.94% from the previous year’s levels. The total energy consumption has been reducing on a YOY basis.
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
Pharma marketing exec on how health brands are trading clinical claims for cultural currency—and what the FDA's latest warning means for the future.
Definium's CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.
Join The Discussion